1. Home
  2. GOODO vs LYEL Comparison

GOODO vs LYEL Comparison

Compare GOODO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share

GOODO

Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share

N/A

Current Price

$18.75

Market Cap

0.0

Sector

Real Estate

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$9.43

Market Cap

320.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GOODO
LYEL
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
320.1M
IPO Year
2003
2021

Fundamental Metrics

Financial Performance
Metric
GOODO
LYEL
Price
$18.75
$9.43
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $37.88
AVG Volume (30 Days)
5.4K
★ 105.0K
Earning Date
N/A
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.18
N/A
Revenue
★ $161,336,000.00
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$106.22
★ N/A
Revenue Growth
★ 8.00
N/A
52 Week Low
$19.01
$9.45
52 Week High
$22.20
$45.00

Technical Indicators

Market Signals
Indicator
GOODO
LYEL
Relative Strength Index (RSI) 25.52 27.89
Support Level N/A N/A
Resistance Level $20.32 $15.38
Average True Range (ATR) 0.30 0.52
MACD -0.15 -0.09
Stochastic Oscillator 10.77 12.67

Price Performance

Historical Comparison
GOODO
LYEL

About GOODO Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share

Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: